Product Information
MEPROBAMATE 400 MG TABLET is a generic product labeled by Cipla USA Inc., priced at $5.8924 per EA under NDC 69097097507. Its NADAC has been published 181 times since Apr 20, 2022.
FDA first approved this application on Feb 27, 2008. Its Orange Book therapeutic-equivalence code is AA.
Strength
400 mg/1
Manufacturer
Cipla USA Inc.NDC
69097097507
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MEPROBAMATEApproval Type
Generic (ANDA)
FDA Application
ANDA040797FDA Approved
2/27/2008
TE Code
AA
On Market Since
6/7/2021
Price Statistics
The NADAC for MEPROBAMATE 400 MG TABLET has been published 181 times since Apr 20, 2022, and over the history we have for it it has risen 16.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.8924 per EA |
|---|---|
| All-time high | $6.0533 (Dec 10, 2025) |
| All-time low | $4.9689 (Aug 21, 2024) |
| 52-week high | $6.0533 |
| 52-week low | $5.7297 |
| Median price | $5.5906 |
| Average price | $5.4901 |
| Largest weekly change | +14.6% (Oct 23, 2024) |
| Weeks tracked | 181 |
| Tracking since | Apr 20, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Meprobamate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MEPROBAMATE 400 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MEPROBAMATE 400 MG TABLET, manufactured by Cipla USA Inc., is $5.8924 per EA (NDC 69097097507), effective Sep 30, 2026.
How has the price of MEPROBAMATE 400 MG TABLET changed over time?
Over the history we have for it, the NADAC for MEPROBAMATE 400 MG TABLET has risen 16.1%. It has been tracked across 181 weekly CMS publications since Apr 20, 2022.
What are the highest and lowest recorded NADAC prices for MEPROBAMATE 400 MG TABLET?
Since Apr 20, 2022, the NADAC for MEPROBAMATE 400 MG TABLET has ranged from a low of $4.9689 (Aug 21, 2024) to a high of $6.0533 (Dec 10, 2025), with a median of $5.5906 per EA.
Are there cheaper alternatives to MEPROBAMATE 400 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as MEPROBAMATE 400 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures MEPROBAMATE 400 MG TABLET?
MEPROBAMATE 400 MG TABLET (NDC 69097097507) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.